Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR.

Mouawad M, Biernaski H, Brackstone M, Lock M, Yaremko B, Shmuilovich O, Kornecki A, Ben Nachum I, Muscedere G, Lynn K, Prato FS, Thompson RT, Gaede S, Gelman N.

Clin Transl Radiat Oncol. 2019 Dec 25;21:25-31. doi: 10.1016/j.ctro.2019.12.004. eCollection 2020 Mar.

2.

Incorporating Pathology-Induced Heterogeneities in a Patient-Specific Biomechanical Model of the Lung for Accurate Tumor Motion Estimation.

Jafari P, Hoover DA, Yaremko BP, Parraga G, Samani A, Sadeghi-Naini A.

Conf Proc IEEE Eng Med Biol Soc. 2019 Jul;2019:6964-6967. doi: 10.1109/EMBC.2019.8856707.

PMID:
31947441
3.

4DCT Ventilation Map Construction Using Biomechanics-base Image Registration and Enhanced Air Segmentation.

Jafari P, Yaremko BP, Parraga G, Hoover DA, Sadeghi-Naini A, Samani A.

Conf Proc IEEE Eng Med Biol Soc. 2019 Jul;2019:6263-6266. doi: 10.1109/EMBC.2019.8857931.

PMID:
31947274
4.

A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases.

Rodrigues G, Yartsev S, Roberge D, MacRae R, Roa WH, Panet-Raymond V, Masucci GL, Yaremko BP, D'Souza D, Palma D, Sexton T, Yu E, Pantarotto J, Ahmad B, Fisher B, Dar AR, Lambert C, Pond G, Tay KY, Bauman G.

Cureus. 2019 Dec 16;11(12):e6394. doi: 10.7759/cureus.6394.

5.

Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.

Palma DA, Chen H, Bahig H, Gaede S, Harrow S, Laba JM, Qu XM, Rodrigues GB, Yaremko BP, Yu E, Louie AV, Dhaliwal I, Ryerson CJ.

BMC Cancer. 2019 Dec 11;19(1):1206. doi: 10.1186/s12885-019-6392-8.

6.

Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.

Olson R, Senan S, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D.

Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):943-947. doi: 10.1016/j.ijrobp.2019.08.041. Epub 2019 Aug 27.

PMID:
31470091
7.

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, Rodrigues GB, Lock M, Yaremko BP, Bauman GS, Ahmad B, Schellenberg D, Liu M, Gaede S, Laba J, Mulroy L, Senthi S, Louie AV, Swaminath A, Chalmers A, Warner A, Slotman BJ, de Gruijl TD, Allan A, Senan S.

BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6.

8.

Stereotactic image-guided neoadjuvant ablative single-dose radiation, then lumpectomy, for early breast cancer: the SIGNAL prospective single-arm trial of single-dose radiation therapy.

Guidolin K, Yaremko B, Lynn K, Gaede S, Kornecki A, Muscedere G, BenNachum I, Shmuilovich O, Mouawad M, Yu E, Sexton T, Gelman N, Moiseenko V, Brackstone M, Lock M.

Curr Oncol. 2019 Jun;26(3):e334-e340. doi: 10.3747/co.26.4479. Epub 2019 Jun 1.

9.

Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy.

Gil KM, Pugh SL, Klopp AH, Yeung AR, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Kachnic LA, Bruner DW.

Gynecol Oncol. 2019 Jul;154(1):183-188. doi: 10.1016/j.ygyno.2019.04.682. Epub 2019 May 16.

PMID:
31104905
10.

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S.

Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11.

PMID:
30982687
11.

Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

Palma DA, Nguyen TK, Louie AV, Malthaner R, Fortin D, Rodrigues GB, Yaremko B, Laba J, Kwan K, Gaede S, Lee T, Ward A, Warner A, Inculet R.

JAMA Oncol. 2019 May 1;5(5):681-688. doi: 10.1001/jamaoncol.2018.6993.

PMID:
30789648
12.

Reducing the dose of gadolinium-based contrast agents for DCE-MRI guided SBRT: The effects on inter and intra observer variability for preoperative target volume delineation in early stage breast cancer patients.

Mouawad M, Biernaski H, Brackstone M, Lock M, Yaremko B, Sexton T, Yu E, Dinniwell RE, Lynn K, Hajdok G, Prato FS, Thompson RT, Gelman N, Gaede S.

Radiother Oncol. 2019 Feb;131:60-65. doi: 10.1016/j.radonc.2018.11.020. Epub 2018 Dec 29.

PMID:
30773188
13.

Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid 18 F-fluorodeoxyglucose-positron emission tomography and CT perfusion study.

Yang DM, Palma D, Louie A, Malthaner R, Fortin D, Rodrigues G, Yaremko B, Laba J, Gaede S, Warner A, Inculet R, Lee TY.

J Med Imaging Radiat Oncol. 2019 Feb;63(1):94-101. doi: 10.1111/1754-9485.12807. Epub 2018 Oct 3.

PMID:
30281918
14.

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.

Borrie AE, Rose RV, Choi YH, Perera FE, Read N, Sexton T, Lock M, Vandenberg TA, Hahn K, Dinniwell R, Younus J, Logan D, Potvin K, Yaremko B, Yu E, Lenehan J, Welch S, Tyndale RF, Teft WA, Kim RB.

Breast Cancer Res Treat. 2018 Nov;172(2):371-379. doi: 10.1007/s10549-018-4910-z. Epub 2018 Aug 9.

PMID:
30094551
15.

Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.

Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW.

J Clin Oncol. 2018 Aug 20;36(24):2538-2544. doi: 10.1200/JCO.2017.77.4273. Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Mar 20;37(9):761.

16.

Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer.

Zhang TW, Rodrigues GB, Louie AV, Palma D, Dar AR, Dingle B, Kocha W, Sanatani M, Yaremko B, Yu E, Younus J, Vincent MD.

Curr Oncol. 2018 Feb;25(1):22-31. doi: 10.347/co.25.3657. Epub 2018 Feb 28.

17.

Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).

Palma DA, Nguyen TK, Kwan K, Gaede S, Landis M, Malthaner R, Fortin D, Louie AV, Frechette E, Rodrigues GB, Yaremko B, Yu E, Dar AR, Lee TY, Gratton A, Warner A, Ward A, Inculet R.

Radiat Oncol. 2017 Jan 27;12(1):30. doi: 10.1186/s13014-017-0770-7.

18.

A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy.

Cecchini MJ, Yu E, Yaremko BP, Boldt RG, Potvin K, Sexton T, D'Souza D, Brackstone M, Lock M.

Cureus. 2016 Apr 3;8(4):e555. doi: 10.7759/cureus.555.

19.

Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases.

Bauman G, Yartsev S, Roberge D, MacRae R, Roa W, Panet-Raymond V, Masucci L, Yaremko B, D'Souza D, Palma D, Sexton T, Yu E, Pantarotto JR, Ahmad B, Fisher B, Dar AR, Lambert C, Pond G, Stitt L, Tay KY, Rodrigues G.

J Neurooncol. 2016 Jul;128(3):431-6. doi: 10.1007/s11060-016-2128-7. Epub 2016 Apr 15.

PMID:
27084705
20.

Intensity-Modulated Radiation Therapy Versus 3D Conformal Radiotherapy for Postoperative Gynecologic Cancer: Are They Covering the Same Planning Target Volume?

Lukovic J, Patil N, D'souza D, Millman B, Yaremko BP, Leung E, Whiston F, Hajdok G, Wong E.

Cureus. 2016 Jan 25;8(1):e467. doi: 10.7759/cureus.467.

21.

A proposed framework for consensus-based lung tumour volume auto-segmentation in 4D computed tomography imaging.

Martin S, Brophy M, Palma D, Louie AV, Yu E, Yaremko B, Ahmad B, Barron JL, Beauchemin SS, Rodrigues G, Gaede S.

Phys Med Biol. 2015 Feb 21;60(4):1497-518. doi: 10.1088/0031-9155/60/4/1497. Epub 2015 Jan 22.

PMID:
25611494
22.

Magnetic resonance imaging biomarkers of chronic obstructive pulmonary disease prior to radiation therapy for non-small cell lung cancer.

Sheikh K, Capaldi DP, Hoover DA, Palma DA, Yaremko BP, Parraga G.

Eur J Radiol Open. 2015 May 26;2:81-9. doi: 10.1016/j.ejro.2015.05.003. eCollection 2015.

23.

Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial.

Hoover DA, Capaldi DP, Sheikh K, Palma DA, Rodrigues GB, Dar AR, Yu E, Dingle B, Landis M, Kocha W, Sanatani M, Vincent M, Younus J, Kuruvilla S, Gaede S, Parraga G, Yaremko BP.

BMC Cancer. 2014 Dec 11;14:934. doi: 10.1186/1471-2407-14-934.

24.

Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature.

Kaster TS, Yaremko B, Palma DA, Rodrigues GB.

Clin Lung Cancer. 2015 Mar;16(2):71-9. doi: 10.1016/j.cllc.2014.08.002. Epub 2014 Sep 28. Review.

PMID:
25450876
25.

Impact of target volume segmentation accuracy and variability on treatment planning for 4D-CT-based non-small cell lung cancer radiotherapy.

Martin S, Johnson C, Brophy M, Palma DA, Barron JL, Beauchemin SS, Louie AV, Yu E, Yaremko B, Ahmad B, Rodrigues GB, Gaede S.

Acta Oncol. 2015 Mar;54(3):322-32. doi: 10.3109/0284186X.2014.970666. Epub 2014 Oct 28.

PMID:
25350526
26.

SPECT-based functional lung imaging for the prediction of radiation pneumonitis: a clinical and dosimetric correlation.

Hoover DA, Reid RH, Wong E, Stitt L, Sabondjian E, Rodrigues GB, Jaswal JK, Yaremko BP.

J Med Imaging Radiat Oncol. 2014 Apr;58(2):214-22. doi: 10.1111/1754-9485.12145. Epub 2013 Dec 25.

PMID:
24373453
27.

RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.

Schefter T, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, Small W Jr, Sause W, Gaffney D; Radiation Therapy Oncology Group (RTOG).

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):101-5. doi: 10.1016/j.ijrobp.2013.10.022.

PMID:
24331655
28.

Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.

Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, Slotman BJ, Yaremko BP, Senan S, Palma DA.

Lung Cancer. 2013 Oct;82(1):95-102. doi: 10.1016/j.lungcan.2013.07.023. Epub 2013 Aug 6.

PMID:
23973202
29.

Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction.

Yaremko BP, Palma DA, Erickson AL, Pierce G, Malthaner RA, Inculet RI, Dar AR, Rodrigues GB, Yu E.

Radiat Oncol. 2013 Feb 11;8:33. doi: 10.1186/1748-717X-8-33.

30.

Dosimetry study of [I-131] and [I-125]- meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis.

Roa WH, Yaremko B, McEwan A, Amanie J, Yee D, Cho J, McQuarrie S, Riauka T, Sloboda R, Wiebe L, Loebenberg R, Janicki C.

Technol Cancer Res Treat. 2013 Feb;12(1):79-90. doi: 10.7785/tcrt.2012.500301. Epub 2012 Sep 15.

PMID:
22974332
31.

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.

Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S.

BMC Cancer. 2012 Jul 23;12:305. doi: 10.1186/1471-2407-12-305.

32.

Sci-Fri AM: Imaging - 04: SPECT-based functional lung imaging in the prediction of radiation pneumonitis: A retrospective clinical and dosimetric correlation.

Hoover D, Reid RH, Rodrigues G, Wong E, Stitt L, Yaremko BP.

Med Phys. 2012 Jul;39(7Part4):4640-4641. doi: 10.1118/1.4740190.

PMID:
28516660
33.

Poster - Thur Eve - 16: Four-dimensional x-ray computed tomography and hyperpolarized 3 He magnetic resonance imaging of gas distribution in lung cancer.

Mathew L, Castillo R, Castillo E, Yaremko B, Rodrigues G, Etemad-Rezai R, Guerrero T, Parraga G.

Med Phys. 2012 Jul;39(7Part2):4627. doi: 10.1118/1.4740124.

PMID:
28516547
34.

Intensity-modulated radiotherapy in the treatment of gynaecological cancers.

D'Souza DP, Rumble RB, Fyles A, Yaremko B, Warde P; Members of the IMRT Indications Expert Panel.

Clin Oncol (R Coll Radiol). 2012 Sep;24(7):499-507. doi: 10.1016/j.clon.2012.05.005. Epub 2012 Jun 13. Review.

PMID:
22703725
35.

A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.

Schefter TE, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, Small W Jr, Gaffney DK.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1179-84. doi: 10.1016/j.ijrobp.2011.10.060. Epub 2012 Feb 16.

PMID:
22342094
36.

An evaluation of an automated 4D-CT contour propagation tool to define an internal gross tumour volume for lung cancer radiotherapy.

Gaede S, Olsthoorn J, Louie AV, Palma D, Yu E, Yaremko B, Ahmad B, Chen J, Bzdusek K, Rodrigues G.

Radiother Oncol. 2011 Nov;101(2):322-8. doi: 10.1016/j.radonc.2011.08.036. Epub 2011 Oct 6.

PMID:
21981879
37.

An early report on outcomes from computed tomographic-based high-dose-rate brachytherapy for locally advanced cervix cancer: A single institution experience.

Hallock A, Surry K, Batchelar D, Vanderspek L, Yuen J, Hammond A, Radwan J, Yaremko B, Rodrigues G, D'Souza D.

Pract Radiat Oncol. 2011 Jul-Sep;1(3):173-81. doi: 10.1016/j.prro.2011.01.004. Epub 2011 May 14.

PMID:
24673947
38.

A pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain metastases.

Rodrigues G, Eppinga W, Lagerwaard F, de Haan P, Haasbeek C, Perera F, Slotman B, Yaremko B, Yartsev S, Bauman G.

Radiother Oncol. 2012 Feb;102(2):180-6. doi: 10.1016/j.radonc.2011.05.032.

PMID:
21641067
39.

Pain and symptom assessment during multiple fractions of gynecologic high-dose-rate brachytherapy.

Wiebe E, Surry K, Derrah L, Murray T, Hammond A, Yaremko B, D'Souza D.

Brachytherapy. 2011 Sep-Oct;10(5):352-6. doi: 10.1016/j.brachy.2011.04.001. Epub 2011 Jun 2.

PMID:
21640664
40.

What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer?

Yu E, Tai P, Malthaner R, Stitt L, Rodrigues G, Dar R, Yaremko B, Younus J, Sanatani M, Vincent M, Dingle B, Fortin D, Inculet R.

Curr Oncol. 2010 Nov;17(6):46-51.

41.

SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics.

Basso AD, Liu M, Dai C, Gray K, Nale L, Tevar S, Lee S, Liang L, Ponery A, Yaremko B, Smith E, Tang H, Sheth PR, Siddiqui MA, Hicklin DJ, Kirschmeier P.

Mol Cancer Ther. 2010 Nov;9(11):2993-3002. doi: 10.1158/1535-7163.MCT-10-0548. Epub 2010 Oct 26.

42.

Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.

Louie AV, Rodrigues G, Hannouf M, Zaric GS, Palma DA, Cao JQ, Yaremko BP, Malthaner R, Mocanu JD.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):964-73. doi: 10.1016/j.ijrobp.2010.06.040. Epub 2010 Oct 6.

PMID:
20932688
43.

Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.

Belanger DB, Williams MJ, Curran PJ, Mandal AK, Meng Z, Rainka MP, Yu T, Shih NY, Siddiqui MA, Liu M, Tevar S, Lee S, Liang L, Gray K, Yaremko B, Jones J, Smith EB, Prelusky DB, Basso AD.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43. doi: 10.1016/j.bmcl.2010.08.140. Epub 2010 Sep 18.

PMID:
20855207
44.

Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases.

Rodrigues G, Yartsev S, Yaremko B, Perera F, Dar AR, Hammond A, Lock M, Yu E, Ash R, Caudrelier JM, Khuntia D, Bailey L, Bauman G.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1128-33. doi: 10.1016/j.ijrobp.2010.03.047. Epub 2010 Aug 2.

PMID:
20675078
45.

Analysis of a novel protocol of combined induction chemotherapy and concurrent chemoradiation in unresected non-small-cell lung cancer: a ten-year experience with vinblastine, Cisplatin, and radiation therapy.

Waters E, Dingle B, Rodrigues G, Vincent M, Ash R, Dar R, Inculet R, Kocha W, Malthaner R, Sanatani M, Stitt L, Yaremko B, Younus J, Yu E.

Clin Lung Cancer. 2010 Jul 1;11(4):243-50. doi: 10.3816/CLC.2010.n.031.

PMID:
20630826
46.

Intensity modulated radiotherapy of non-small-cell lung cancer incorporating SPECT ventilation imaging.

Munawar I, Yaremko BP, Craig J, Oliver M, Gaede S, Rodrigues G, Yu E, Reid RH, Leung E, Urbain JL, Chen J, Wong E.

Med Phys. 2010 Apr;37(4):1863-72.

PMID:
20443508
47.

Inter-observer and intra-observer reliability for lung cancer target volume delineation in the 4D-CT era.

Louie AV, Rodrigues G, Olsthoorn J, Palma D, Yu E, Yaremko B, Ahmad B, Aivas I, Gaede S.

Radiother Oncol. 2010 May;95(2):166-71. doi: 10.1016/j.radonc.2009.12.028. Epub 2010 Feb 1.

PMID:
20122749
48.

Postoperative extended-volume external-beam radiation therapy in high-risk esophageal cancer patients: a prospective experience.

Yu E, Tai P, Younus J, Malthaner R, Truong P, Stitt L, Rodrigues G, Ash R, Dar R, Yaremko B, Tomiak A, Dingle B, Sanatani M, Vincent M, Kocha W, Fortin D, Inculet R.

Curr Oncol. 2009 Aug;16(4):48-54.

49.

Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer.

Louie AV, Rodrigues G, Yaremko B, Yu E, Dar AR, Dingle B, Vincent M, Sanatani M, Younus J, Malthaner R, Inculet R.

Clin Lung Cancer. 2009 May;10(3):174-9. doi: 10.3816/CLC.2009.n.024.

PMID:
19443337
50.

Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy.

Rose J, Rodrigues G, Yaremko B, Lock M, D'Souza D.

Radiother Oncol. 2009 Jun;91(3):282-7. doi: 10.1016/j.radonc.2008.09.010. Epub 2008 Oct 22. Review.

PMID:
18950881

Supplemental Content

Loading ...
Support Center